Charles River Laboratories Debt to Equity Ratio 2010-2024 | CRL
Current and historical debt to equity ratio values for Charles River Laboratories (CRL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Charles River Laboratories debt/equity for the three months ending June 30, 2024 was 0.65.
| Charles River Laboratories Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$4.22B |
$3.73B |
1.13 |
| 2024-03-31 |
$4.51B |
$3.65B |
1.24 |
| 2023-12-31 |
$4.59B |
$3.60B |
1.28 |
| 2023-09-30 |
$4.30B |
$3.31B |
1.30 |
| 2023-06-30 |
$4.52B |
$3.26B |
1.39 |
| 2023-03-31 |
$4.59B |
$3.11B |
1.47 |
| 2022-12-31 |
$4.62B |
$2.98B |
1.55 |
| 2022-09-30 |
$4.75B |
$2.63B |
1.80 |
| 2022-06-30 |
$4.88B |
$2.65B |
1.84 |
| 2022-03-31 |
$4.46B |
$2.62B |
1.71 |
| 2021-12-31 |
$4.49B |
$2.54B |
1.77 |
| 2021-09-30 |
$4.63B |
$2.43B |
1.90 |
| 2021-06-30 |
$4.40B |
$2.32B |
1.89 |
| 2021-03-31 |
$3.62B |
$2.19B |
1.66 |
| 2020-12-31 |
$3.37B |
$2.12B |
1.59 |
| 2020-09-30 |
$3.31B |
$1.90B |
1.74 |
| 2020-06-30 |
$3.48B |
$1.76B |
1.98 |
| 2020-03-31 |
$3.55B |
$1.66B |
2.14 |
| 2019-12-31 |
$3.06B |
$1.64B |
1.87 |
| 2019-09-30 |
$3.05B |
$1.54B |
1.98 |
| 2019-06-30 |
$3.17B |
$1.46B |
2.17 |
| 2019-03-31 |
$2.53B |
$1.40B |
1.80 |
| 2018-12-31 |
$2.54B |
$1.32B |
1.92 |
| 2018-09-30 |
$2.54B |
$1.26B |
2.02 |
| 2018-06-30 |
$2.68B |
$1.19B |
2.26 |
| 2018-03-31 |
$1.86B |
$1.14B |
1.63 |
| 2017-12-31 |
$1.88B |
$1.05B |
1.80 |
| 2017-09-30 |
$1.84B |
$1.03B |
1.80 |
| 2017-06-30 |
$1.81B |
$0.97B |
1.87 |
| 2017-03-31 |
$1.82B |
$0.88B |
2.07 |
| 2016-12-31 |
$1.87B |
$0.84B |
2.23 |
| 2016-09-30 |
$1.82B |
$0.87B |
2.08 |
| 2016-06-30 |
$1.93B |
$0.84B |
2.30 |
| 2016-03-31 |
$1.32B |
$0.78B |
1.68 |
| 2015-12-31 |
$1.33B |
$0.74B |
1.81 |
| 2015-09-30 |
$1.32B |
$0.71B |
1.87 |
| 2015-06-30 |
$1.18B |
$0.71B |
1.67 |
| 2015-03-31 |
$1.18B |
$0.67B |
1.77 |
| 2014-12-31 |
$1.20B |
$0.68B |
1.77 |
| 2014-09-30 |
$1.17B |
$0.67B |
1.73 |
| 2014-06-30 |
$1.19B |
$0.68B |
1.76 |
| 2014-03-31 |
$0.95B |
$0.70B |
1.36 |
| 2013-12-31 |
$0.99B |
$0.64B |
1.54 |
| 2013-09-30 |
$0.98B |
$0.66B |
1.49 |
| 2013-06-30 |
$0.97B |
$0.65B |
1.49 |
| 2013-03-31 |
$0.97B |
$0.63B |
1.54 |
| 2012-12-31 |
$0.98B |
$0.60B |
1.63 |
| 2012-09-30 |
$0.97B |
$0.60B |
1.61 |
| 2012-06-30 |
$0.98B |
$0.57B |
1.74 |
| 2012-03-31 |
$1.00B |
$0.56B |
1.81 |
| 2011-12-31 |
$1.03B |
$0.53B |
1.96 |
| 2011-09-30 |
$1.04B |
$0.54B |
1.93 |
| 2011-06-30 |
$1.12B |
$0.59B |
1.89 |
| 2011-03-31 |
$1.18B |
$0.56B |
2.09 |
| 2010-12-31 |
$1.05B |
$0.69B |
1.52 |
| 2010-09-30 |
$1.04B |
$1.04B |
1.00 |
| 2010-06-30 |
$0.76B |
$1.39B |
0.55 |
| 2010-03-31 |
$0.80B |
$1.38B |
0.58 |
| 2009-12-31 |
$0.83B |
$1.37B |
0.60 |
| 2009-09-30 |
$0.84B |
$1.35B |
0.62 |
| 2009-06-30 |
$0.87B |
$1.28B |
0.68 |
| 2009-03-31 |
$0.87B |
$1.22B |
0.71 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$9.742B |
$4.129B |
|
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
|
